US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Altech Digitial Co.

44.27

0.0000

Volume:- -

Turnover:- -

Market Cap:1.31B

PE:- -

High:44.27

Open:44.27

Low:44.27

Close:44.27

52wk High:44.27

52wk Low:44.27

Shares:29.50M

Float Shares:29.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:259.58%

ROA:48.64%

PB:1367.53

PE(LYR):- -

Loading ...

Overview Company News Filings

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Ampol reports lapse of 42,749 performance rights

Ampol Issues 114,737 New Ordinary Shares Following Security Conversions

Ampol secures A$400m delayed‑draw hybrid to fund refinancing

Applied Materials Unveils Deposition and Selective Etch Systems to Advance 3D Chip Scaling

Ampol Issues 203,386 Unquoted Performance Rights Under Employee Incentive Scheme

Ampol Scraps Planned Share Issue, Opts for Cash Settlement

ACCC Clears Ampol’s EG Australia Takeover With Forced Site Sell-Off

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

Altimmune to Participate in Upcoming Investor Conferences

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Altimmune Announces First Quarter 2026 Financial Results and Business Update

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Ampol outlines 2025 performance and outlook at Macquarie Australia Conference

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

AI Infrastructure Stocks Are Leaving the ‘Old Economy’ Behind

Ampol Ups Site Divestments in Final Remedy Offer for EG Australia Deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ALD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"Altech Digitial Co.","latestPrice":44.27,"timestamp":1787342400000,"preClose":44.27,"halted":9,"volume":0,"delay":0,"changeRate":0,"floatShares":29500000,"shares":29500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:00:00 EDT","open":44.27,"high":44.27,"low":44.27,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1767070800000,"exchange":"NASDAQ","adjPreClose":44.27,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":29500000,"roa":"48.64%","roe":"259.58%","lyrEps":0,"shares":29500000,"dividePrice":0,"high":44.27,"amplitude":0,"preClose":44.27,"low":44.27,"week52Low":44.27,"pbRate":"1367.53","psRate":"374.12","week52High":44.27,"institutionHeld":0,"latestPrice":44.27,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":44.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658908647","title":"Altimmune Announces Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908647?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD  $519 million in cash, cas","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343554/0/en/altimmune-announces-second-quarter-2026-financial-results-and-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","LU1242518931.SGD","IR","BK4161","LU1242518857.USD","SG9999001440.SGD","LU0256863902.USD","BBC","BK4588","LU1559883803.SGD","LU0566484027.USD","PSIL","BK4183","CROC","LU1978683503.SGD","ELF","LU0124384867.USD","LU0256863811.USD","BK4585","LU0417517546.SGD","ALD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657954224","title":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657954224","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657954224?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:00","pubTimestamp":1785931200,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Aug.  05, 2026  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339241/0/en/Altimmune-to-Report-Second-Quarter-2026-Financial-Results-and-Provide-Business-Update-on-August-12-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004353","title":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004353","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004353?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":"Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, incl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334113/0/en/Altimmune-Announces-Positive-Topline-Results-from-RECLAIM-Phase-2-Trial-of-Pemvidutide-in-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU0124384867.USD","LU0256863902.USD","BK4588","LU0417517546.SGD","ALD","LU1978683503.SGD","SG9999001440.SGD","BK4585","LU0256863811.USD","CROC","IR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650941299","title":"Ampol reports lapse of 42,749 performance rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2650941299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650941299?lang=en_us&edition=fundamental","pubTime":"2026-07-09 15:17","pubTimestamp":1783581449,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) just unveiled an update. Ampol Limited has updated the market on changes to its capital structure, notifying the lapse ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-reports-lapse-of-42749-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-reports-lapse-of-42749-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650412389","title":"Ampol Issues 114,737 New Ordinary Shares Following Security Conversions","url":"https://stock-news.laohu8.com/highlight/detail?id=2650412389","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650412389?lang=en_us&edition=fundamental","pubTime":"2026-07-09 15:10","pubTimestamp":1783581026,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) has provided an update. Ampol Limited has notified the ASX of the issue of 114,737 ordinary fully paid shares following...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-issues-114737-new-ordinary-shares-following-security-conversions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-issues-114737-new-ordinary-shares-following-security-conversions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646838212","title":"Ampol secures A$400m delayed‑draw hybrid to fund refinancing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646838212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646838212?lang=en_us&edition=fundamental","pubTime":"2026-06-26 08:15","pubTimestamp":1782432936,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) just unveiled an announcement. Ampol has launched a new A$400 million delayed‑draw subordinated notes facility as part ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-secures-a400m-delayeddraw-hybrid-to-fund-refinancing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-secures-a400m-delayeddraw-hybrid-to-fund-refinancing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785639","title":"Applied Materials Unveils Deposition and Selective Etch Systems to Advance 3D Chip Scaling","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785639","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785639?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:05","pubTimestamp":1781553900,"startTime":"0","endTime":"0","summary":"New systems enable precision materials engineering in high-aspect-ratio 3D logic and memory chip structuresCentris Spectral SiN ALD leverages innovative microwave plasma technology to deliver uniform ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3312128/0/en/Applied-Materials-Unveils-Deposition-and-Selective-Etch-Systems-to-Advance-3D-Chip-Scaling.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","LU0868494708.USD","LU0274383776.USD","IE00BD6J9T35.USD","LU1868836591.USD","LU2089985449.USD","LU1989763005.USD","IE00B5949003.HKD","LU1642822529.SGD","AIYY","CHAT","LU2111349929.HKD","LU0949170772.SGD","ALD","ARTY","LU0354030511.USD","LU1989773731.SGD","ARKG","AMAT","LU2413666699.HKD","IE00BSNM7G36.USD","LU1003077747.HKD","IE00BFXG1179.USD","IE00BQXX3C00.GBP","BK4528","LU1868837300.USD","LU0661504455.SGD","LU2413666426.HKD","DRAM","LU1868836757.USD","LU0347712357.USD","LU1868836914.USD","LU1803068979.SGD","AGIX","LU1674673691.USD","LU0289960550.SGD","LU0738911758.USD","LU1823568750.SGD","LU2023250843.SGD","AI","BK4585","UYM","BK4587","GAA","LU0198837287.USD","LU1153585028.USD","BK4519","AIPO","IE0009356076.USD","LU0889565833.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641089190","title":"Ampol Issues 203,386 Unquoted Performance Rights Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2641089190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641089190?lang=en_us&edition=fundamental","pubTime":"2026-06-05 14:48","pubTimestamp":1780642086,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Ampol Limited ( ($AU:ALD) ). Ampol Limited has notified the market of the issue of 203,386 unquoted performance...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-issues-203386-unquoted-performance-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-issues-203386-unquoted-performance-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640924802","title":"Ampol Scraps Planned Share Issue, Opts for Cash Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640924802","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640924802?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:52","pubTimestamp":1780444339,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) just unveiled an update. Ampol Limited has notified the ASX that it is cancelling a previously announced proposed issue...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-scraps-planned-share-issue-opts-for-cash-settlement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-scraps-planned-share-issue-opts-for-cash-settlement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640212849","title":"ACCC Clears Ampol’s EG Australia Takeover With Forced Site Sell-Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2640212849","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640212849?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:28","pubTimestamp":1780442916,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) has issued an update. Australia’s competition regulator has cleared Ampol’s acquisition of EG Australia, a major fuel a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/accc-clears-ampols-eg-australia-takeover-with-forced-site-sell-off?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/accc-clears-ampols-eg-australia-takeover-with-forced-site-sell-off?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4019","BK4588","ALD","LU0077335932.USD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","EG","LU0211331839.USD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692810","title":"Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692810","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638692810?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:00","pubTimestamp":1779980400,"startTime":"0","endTime":"0","summary":"“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to fur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303064/0/en/Pemvidutide-Demonstrates-Significant-Metabolic-Improvements-in-Patients-with-MASH-in-New-48-Week-IMPACT-Phase-2b-Data-Presented-at-EASL-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4183","LU1242518931.SGD","ELF","LU1242518857.USD","LU0566484027.USD","BK4585","LU0053671581.USD","LU0979878070.USD","ALD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638883386","title":"Altimmune to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638883386","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638883386?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:30","pubTimestamp":1779885000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., May  27, 2026   -- Altimmune, Inc. , a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis , alcohol use disorder  and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301939/0/en/Altimmune-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638008507","title":"New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638008507","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638008507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883200,"startTime":"0","endTime":"0","summary":"Concurrent improvement across key non-invasive tests underscores convergence ofpemvidutide effects on MASH disease activity and fibrosis  AI-based digital pathology analyses further demonstrate antifi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301887/0/en/New-IMPACT-Phase-2b-Data-Highlight-Concurrent-Improvements-Across-Multiple-Non-Invasive-Markers-and-qFibrosis-Measured-Fibrosis-Regression-with-Pemvidutide-in-MASH-at-EASL-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0979878070.USD","LU0053671581.USD","SHG","BK4139","ALD","LU0566484027.USD","LU1242518857.USD","BK4207","LU1242518931.SGD","LU1559883803.SGD","LU1878469433.USD","ELF","ALT","BK4599","BK4183","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635890457","title":"Altimmune Announces First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635890457","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635890457?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:30","pubTimestamp":1778671800,"startTime":"0","endTime":"0","summary":"Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET G","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293891/0/en/Altimmune-Announces-First-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1978683503.SGD","BK4161","LU0256863902.USD","LU0417517546.SGD","ALD","IR","LU0124384867.USD","BK4585","LU0256863811.USD","SG9999001440.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789910","title":"Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789910","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789910?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:15","pubTimestamp":1778670900,"startTime":"0","endTime":"0","summary":"Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL Oral presentation will highlight further the 48-week IMPACT efficacy and safe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293871/0/en/Altimmune-to-Present-Results-of-Pemvidutide-in-MASH-in-an-Oral-Presentation-and-Multiple-Poster-Presentations-at-EASL-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633971180","title":"Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633971180","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633971180?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., May  06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today anno","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288706/0/en/Altimmune-to-Report-First-Quarter-2026-Financial-Results-and-Provide-Business-Update-on-May-13-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633967606","title":"Ampol outlines 2025 performance and outlook at Macquarie Australia Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633967606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633967606?lang=en_us&edition=fundamental","pubTime":"2026-05-05 07:38","pubTimestamp":1777937934,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) just unveiled an update. Ampol Limited has released a presentation for investors at the Macquarie Australia Conference,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-outlines-2025-performance-and-outlook-at-macquarie-australia-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-outlines-2025-performance-and-outlook-at-macquarie-australia-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630321393","title":"Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2630321393","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630321393?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287600,"startTime":"0","endTime":"0","summary":"$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout  Financing was led by Deep Track Capita","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281472/0/en/Altimmune-Announces-Closing-of-225-Million-Oversubscribed-Public-Offering-of-Securities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629623832","title":"AI Infrastructure Stocks Are Leaving the ‘Old Economy’ Behind","url":"https://stock-news.laohu8.com/highlight/detail?id=2629623832","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629623832?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:55","pubTimestamp":1776948900,"startTime":"0","endTime":"0","summary":"AI infrastructure stocks are surging while traditional firms struggle. Earnings reveal a growing economic divide investors can’t ignore.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/hypergrowthinvesting/2026/04/ai-infrastructure-stocks-are-leaving-the-old-economy-behind/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/hypergrowthinvesting/2026/04/ai-infrastructure-stocks-are-leaving-the-old-economy-behind/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["BK4588","LU2506951792.HKD","LU1721427968.SGD","IE00B894F039.SGD","ARTY","LU2249611893.SGD","VRT","AGIX","LU1543694498.USD","LU2264538146.SGD","LU2098885051.SGD","LU1978683503.SGD","LU2290526834.HKD","LU1620156213.USD","BK4157","LU2357125470.USD","LU0348723411.USD","LU0124384867.USD","VRTL","IE00BMPRXR70.SGD","BK4188","LU0251142724.SGD","AIPO","GEVX","IE00BMPRXN33.USD","BK4023","ASM","LU1988902786.USD","LU1064131342.USD","LU1596574779.USD","LU2065171402.SGD","LU0742534661.SGD","BK4096","GEVG","AI","IE00BN0W2T93.GBP","TDY","LU2543165471.USD","IE00BN0W2V16.EUR","GEV","LU2125909916.SGD","IE00BZ9MQY76.HKD","ALD","LU1923622291.USD","CHAT","BK4587","AIYY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071833","title":"Ampol Ups Site Divestments in Final Remedy Offer for EG Australia Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629071833?lang=en_us&edition=fundamental","pubTime":"2026-04-23 07:07","pubTimestamp":1776899249,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) has issued an update. Ampol has submitted a final remedy offer to the Australian Competition & Consumer Commission for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-ups-site-divestments-in-final-remedy-offer-for-eg-australia-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-ups-site-divestments-in-final-remedy-offer-for-eg-australia-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0211331839.USD","IE0002270589.USD","ALD","EG","BK4019","LU0077335932.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}]}}